Marketing authorization holders in the EU should review all their OTC drugs containing chemically synthesized active pharmaceutical ingredients for the possible presence of nitrosamines and test all products at risk, the European Medicines Agency has requested.
The agency says the evaluation – which also applies to branded and generic prescription drugs – is necessary in light...







